Drug Profile
Research programme: Alzheimer's disease therapeutics - Applied NeuroSolutions/Eli Lilly and Company
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Applied NeuroSolutions
- Developer Applied NeuroSolutions; Eli Lilly and Company
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 23 Dec 2009 Applied NeuroSolutions and Eli Lilly and Company increase the scope of their original three-year Alzheimer's disease drug discovery collaboration
- 09 Dec 2009 Eli Lilly and Company enters into a one-year renewal of its collaboration agreement with Applied NeuroSolutions